Condyline (Podophyllotoxin)

What is Condyline?

Condyline (podophyllotoxin 0.5% solution) is a prescription topical medicine used to treat external genital and perianal warts in adults. It is a purified, standardised extract derived from the roots and rhizomes of Podophyllum plants, and belongs to the antimitotic class of wart treatments.

Unlike immune-modifying treatments such as imiquimod (Aldara), which work by stimulating the immune system, Condyline acts directly on wart tissue by inhibiting cell division in HPV-infected keratinocytes, causing the wart cells to die.

How does Condyline work?

Podophyllotoxin exerts its effect through a well-characterised antimitotic mechanism:

• Tubulin binding: Podophyllotoxin binds to the beta subunit of tubulin, the protein that forms microtubules — the structural scaffold required for cell division.
• Mitotic arrest: By preventing microtubule polymerisation, podophyllotoxin arrests dividing cells in metaphase (the stage of cell division where chromosomes align before separation).
• Cell death: Cells arrested in mitosis cannot complete division and undergo necrosis (cell death), leading to destruction of the wart tissue.
• Selective effect: The effect is most pronounced in rapidly dividing cells, such as the HPV-infected keratinocytes that comprise wart tissue.

The result is a progressive destruction and shedding of the wart over the treatment cycles.

Who is Condyline for?

Condyline is indicated for adults with small to moderate-sized external genital and perianal warts. It is particularly suitable for patients who:

• Have clearly identifiable discrete warts accessible to self-application
• Have confirmed or clinically suspected condylomata acuminata following medical assessment
• Are able to apply the treatment accurately and follow the treatment schedule

Condyline is not appropriate for:

• Internal warts: Condyline should not be applied inside the vagina, urethra, rectum, or on mucous membranes where precise control of application is not possible
• Pregnant women: Podophyllotoxin is contraindicated in pregnancy due to potential teratogenicity and systemic absorption risk
• Children and adolescents: Safety and efficacy have not been established in patients under 18 years
• Large wart areas: Large confluent warts may not be suitable for self-applied topical treatment — a doctor should assess alternatives such as cryotherapy or surgical removal

Posologia e applicazione

Treatment cycle: Apply twice daily (morning and evening) for 3 consecutive days, then stop for 4 days. This constitutes one treatment cycle.

Fase	Durata
Treatment (apply)	Days 1–3
Rest (do not apply)	Days 4–7
Repeat cycle if needed	Up to 4 complete cycles (4 weeks)

Istruzioni per l’applicazione (as per prescribing guidance):

1. Clean the treatment area and allow to dry thoroughly.
2. Using the applicator provided, apply the solution precisely to the surface of each wart. Avoid contact with surrounding healthy skin.
3. Allow the solution to dry before dressing or resuming normal activity.
4. Wash hands thoroughly after application.
5. Do not apply to broken, inflamed, or irritated skin.
6. Avoid sexual contact while the solution is on the skin.

Maximum treatment area: No more than 10 cm² of wart tissue should be treated in any one session, and no more than 50 microlitres of solution per session.

Effetti collaterali

Local reactions are expected and reflect the cytotoxic action of the medicine on wart tissue.

Effetti collaterali comuni

• Burning, stinging, or pain at the application site
• Redness (erythema)
• Erosion or ulceration of treated tissue (a sign the medicine is working)
• Itching
• Tenderness

Effetti collaterali non comuni

• Blistering at the treatment site
• Inflammation of surrounding skin if the solution spreads beyond the wart
• Pigmentation changes (may be prolonged)

Effetti sistemici (con uso eccessivo)

• If used on large areas or for extended periods beyond recommended limits, systemic absorption may cause: nausea, vomiting, peripheral neuropathy, and haematological effects. Use must not exceed the recommended dose or area.

Treatment should be paused if severe local reactions develop and resumed when the skin has recovered.

Condyline vs alternative wart treatments

Trattamento	Principio attivo	Meccanismo	Applicazione
Condyline	Podophyllotoxin 0.5% solution	Antimitotic	3 days on/4 days off, up to 4 cycles
Warticon	Podophyllotoxin 0.15% cream	Antimitotic	Same cycle
Aldara	Imiquimod 5% cream	Immune stimulation	3x/week, up to 16 weeks
Cryotherapy	Liquid nitrogen	Physical destruction	Clinic-based

Condyline vs Warticon: Both contain podophyllotoxin and follow the same treatment cycle. The key differences are in concentration (0.5% solution vs 0.15% cream) and formulation. The cream formulation (Warticon) may be gentler on surrounding skin and easier to apply to moist surfaces. A doctor will advise on the most appropriate formulation.

Condyline vs Aldara: These treatments work through entirely different mechanisms. Aldara (imiquimod) stimulates the immune system rather than directly destroying tissue. Some evidence suggests imiquimod may have lower recurrence rates due to its immune-stimulating properties, but onset of action is slower. The choice depends on individual clinical assessment.

How to access Condyline online in Europe

Condyline è un farmaco soggetto a prescrizione medica in tutti gli stati membri dell’UE. Non può essere legalmente dispensato senza una prescrizione valida da parte di un professionista medico autorizzato.

Prescrivia opera come intermediario tecnologico: non prescriviamo farmaci, non impieghiamo medici né vendiamo medicinali. La nostra piattaforma mette in contatto i pazienti con medici indipendenti registrati nell’UE che possono condurre valutazioni sanitarie online riservate.

Il processo:

1. Completi una valutazione della salute: Describe the warts (size, location, duration), your sexual health history, and any previous treatments.
2. Revisione medica: Un medico indipendente registrato nell’UE esamina la Sua valutazione. If podophyllotoxin is clinically appropriate, they may issue a prescription.
3. Dispensazione in farmacia: La prescrizione viene inviata a una farmacia partner autorizzata dell’UE per la dispensazione e la consegna diretta.

Importante: Prescrivia non garantisce che venga emessa una prescrizione. Tutte le decisioni prescrittive vengono prese in modo indipendente da professionisti medici qualificati.

Informazioni importanti sulla sicurezza

Non utilizzi Condyline se Lei:

• Are pregnant or planning to become pregnant
• Are breastfeeding
• Are allergic to podophyllotoxin or any other ingredient
• Have open wounds or significantly inflamed skin in the treatment area

Informi il Suo medico prima di using Condyline se Lei:

• Are immunocompromised (HIV, immunosuppressant therapy)
• Have previously used any other wart treatments
• Are uncertain whether your skin lesions are genital warts — other conditions (including skin cancer) can resemble warts and must be excluded by a doctor

HPV e trasmissione: Treating visible warts removes the physical lesions but does not eliminate HPV infection. The virus may persist in surrounding skin and can be transmitted to sexual partners even in the absence of visible warts. Barrier contraception (condoms) reduces but does not eliminate transmission risk.

Fonti

Le informazioni mediche presenti in questa pagina si basano sulle seguenti fonti:

• European Medicines Agency (EMA). Podophyllotoxin — Summary of Product Characteristics. Disponibile su: ema.europa.eu
• World Health Organization (WHO). Human papillomavirus (HPV) — Fact sheet. who.int
• von Krogh G, et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sexually Transmitted Infections. 2000;76(3):162–168.

Questo contenuto viene rivisto periodicamente per riflettere le linee guida cliniche aggiornate. Viene fornito esclusivamente a scopo informativo e non costituisce consulenza medica. Consulti sempre un professionista sanitario qualificato per consigli pertinenti alle Sue circostanze di salute individuali.